

## India Macro View

### US Mktg Trip Takeaways – Reforms Get India Back from the Edge

*We recently met over 60 institutional investors in the US. Given the on-going reforms, the timing was perfect, and thanks to a mandatory training program, our trip was split across two weeks (Sept 24 – Oct 5). This gave us the opportunity to gauge investor reactions over a fortnight. The biggest change, in our view, is the significantly renewed investor interest in India.*

- **Changing Investor Reaction - From Skepticism to Acceptance** — In the initial part of our trip, the reforms were met with a lot of skepticism with reactions such as "seems too neat and clean" to "can the govt survive?" But, towards the latter half, seeing the continued momentum and the resolve to stick to decisions, investors admitted that "yes, one was caught flat-footed" and now see (a) growth bottoming out and (b) aversion of a rating downgrade (for now) and early elections.
- **Rating Action Was Key, But in Hindsight Politics Played a Big Role** — There was consensus that reforms were key in averting rating action. However, many investors felt that politics played a big role with the dual leadership of the UPA finally on the same page to revive the economy. They believe this would help improve the fiscal position thus making way for welfare schemes before the next elections.
- **Reforms Good; But What Would Turn Corporate Capex and lower Deficits?** — While there was unanimous relief that the ~2 year long policy log-jam was broken, concern was that structural issues on (a) reducing the deficit and (b) incentivizing investments were yet to be addressed (*See pg 2-7 for commonly asked questions*).
- **Investor Feedback on Asset Classes** — The key takeaway was that in the short term, the fundamental tailwinds (reforms/stabilising commodity prices etc) were strong for India. Thus, in terms of most EMs, India was a preferred destination. But, the consensus worry among investors was "implementation and execution."
  - **Equities:** Most investors said that this was "a painful rally" with many active managers currently underperforming the benchmarks. While India is clearly back on the radar, most investors felt that concrete steps on incentivizing investments would help make the call on "building positions" or "taking profits".
  - **INR:** Investors recognized that reform, global easing and lower commodity prices thanks to China slowing were key to the ~6% INR strength since QE3. However, investors viewed the unit as "being reflexive" given the deficits, declining reserve coverage and inflation-growth mix. While INR remains among the best carry trades, consensus felt that the retracement could stall at USD/INR at ~51 levels
  - **Rates:** Lower commodity prices and the INR strength bode well for inflation. This could prompt monetary easing more than the 50bps currently priced in.

---

**Rohini Malkani**  
+91-22-6631-9876  
rohini.malkani@citi.com

*With thanks to*  
Ipsita Pal, Abha Agarwal

---

#### WHAT'S INSIDE – 10 COMMONLY ASKED QUESTIONS

- Reforms – What's Happened/Next?
  - Capex – What could help it revive?
  - National Invst Board – Can it Help?
  - Kelkar Committee Recos
  - Macro Implications
- 

**See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.**

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

## Reforms – What's Announced and Pending

Following measure on fuel prices on Sept 13 and FDI/Divestments on Sept 14, over the last fortnight, the govt announced a second slew of reforms, and raised hope that there are more to come. Key reforms introduced were FDI in Insurance and Pension, amendments to the Companies Bill, and Forward Contract Regulation Act.

Figure 1. Announced Reforms

Reform	Key Features	Parliament Approval Required?
Fuel Price Hike	Diesel price raised by Rs 5/ltr, Subsidised LPG cylinders capped at 6/household	No
FDI		
Multi-Brand Retail	51% FDI permitted subject to State approval	No
Single- Brand Retail	FDI beyond 51% requires 30% sourcing locally from MSMEs, cottage industries etc.	No
Broadcasting Services	74% FDI allowed in teleports, mobile tv and sky broadcasting services	No
Insurance	49% FDI allowed, public sector insurance cos can get listed with government stake at at least 51%	Yes
Pension	49% FDI, has one term 'return scheme' action, gives statutory power to regulatory authority	Yes
Power Exchanges	49% FDI allowed	No
Civil Aviation	49% FDI in scheduled and non scheduled air transport services	No
Divestment in PSUs	Divestment in MMTC, NALCO, HCL and OIL proceeds ~Rs 150 bn	No
Competition Bill	All sectors under the purview of competition law	Yes
SEB loan restructuring	US\$38bn of loans restructured/converted to state debt	No
Lowering With-holding Tax	With-holding tax lowered from 20% to 5%; Would reduce all in cost by ~75bps	No
Companies Bill (Amendment)	Ensures more transparent corporate governance	Yes
Forward Contract Regulation Act	Facilitate entry of institutional investors, introduce commodity options and derivatives trading	Yes

Source: PIB, Citi Research

While the current reforms have led to a revival in investor sentiment, key pending measures include those on (a) Fiscal consolidation, (b) Incentivizing investments.

- Measures awaited on the fiscal consolidation front include those pertaining to GST, DTC, food/fertiliser subsidies, and finalization of proposals on UTI stake sale in select stocks and surplus land sale.
- As regards incentivizing investments, execution-related obstacles that negatively impact project implementation such as key issues in power, coal, gas, land and environment are yet to be addressed.

All the above, coupled with already announced measures, would help accelerate growth and avert a ratings downgrade.


Figure 2. Pending Reforms

Reform	Key Features
Goods and Services Tax	Landmark Change - for efficiency, GDP and tax collections
Direct Taxes Code	A simplified Tax platform
Land Acquisition Bill	For commercial land acquisition, and Rehabilitation
2G Spectrum Auction	To be completed by January 2013, need to move ahead of scam
Coal Block Allocation	Ongoing, but with high political risks
Environmental Approvals, etc	Big bottleneck, Govt seems aggressively working on it
Fertilizer Subsidy Cut	Urea price hike, less distortion in fertilizer pricing
Shome Committee Report	Looks into investor concerns with GAAR and non-resident taxpayers issues
Food Subsidy Bill	recent recommendations made to cut the subsidy bill
Govt. Surplus Land Sale	to ease fiscal crunch by repaying loans and creating capital assets
Govt. UTI sale in select Stocks	Govt. started talks to sell shares in Axis Bank, ITC, L&T (total holding ~Rs 440bn)

Source: News Reports, Citi Research

## Capex – What could help revive it?


Figure 3. Qtrly Trends in GDP (%)



Source: CSO

The key factor that has led to the deceleration in GDP growth from >8% levels to the last quarterly print of 5.5% has been a near collapse in investments. As mentioned in our earlier notes, this is a result of an amalgamation of factors: (a) lack of sufficient coal/gas; (b) land acquisition/environmental clearance concerns and (c) lack of major government project announcements.

Figure 4. Trends in Projects Stalled (Rs bn)



Source: CMIE, Citi Research

The recurring delay in implementation of important infrastructure projects is partly due to presence of multiple ministries to take decisions on a single project. This delay not only slows down growth, but also adds to costs. As a result, as seen in figure 5 below, this has resulted in India not being able to meet its XIth Five Year Plan Targets.

Figure 5. XIth Five-Year Plan Targets vs. Actuals

Sector	Target	Achievement
Roads	48,479 kms.	Completed – 17,571 kms Under Implementation - 13,981 kms To be awarded - 16,927 kms
Additional power generation capacity created	78,700 MW	55,000 MW
Coal production (per annum)	680 mn tns reduced to 630 mn tns.	540 mn tns
Crude oil production (per annum)	206.73 million tns	177.09 mn tns
Gas production (per annum)	255.76 bn cubic metres	212.5 bn cubic metres
Railways capacity creation	21,500 kms reduced to 15,000 kms	14,752 kms

Source: Planning Commission, PIB, Citi Research

### 1. Addressing Coal Woes

In contrast to annual production targets of 630 million tonnes of coal, India has been producing ~540 million tonnes thus relying on higher imports. In addition to efficiency reasons, despite sitting on cash reserves, Coal India Ltd (CIL) is unable to increase production as 179 of its project proposals remain stuck for approvals. Coal mining requires a gamut of clearances (mining leases, land acquisition, environmental and forest clearances) before becoming operational. The clearances have to follow rigorous procedures which involve many stakeholders and are hence time consuming.

**Figure 6. CIL Projects Pending Clearance**

Pending Stage	No. of Projects
Stage I Clearance	130
Stage II Clearance	49
<b>Total</b>	<b>179</b>

Source: Citi Research

## 2. Land Acquisition Issues

Addressing issues surrounding the acquisition of private, typically agricultural land for public, industrial purposes is key as a progressive land acquisition policy could help speed up projects stalled and pave the way for improved future capital expenditure.

However, complications arise as the legislation in place (Land Acquisition Act, 1894) is dated and does not make adequate provisions for current issues. Moreover, the suggested replacement legislation (The Right to Fair Compensation, Resettlement, Rehabilitation and Transparency in Land Acquisition Bill 2012) is still a matter of political debate as it is viewed as essential for efficient acquisition, yet criticized for prioritizing industry and growth interests over those of the rural population and equality.

The key sectors with stalled projects affected by obstacles to acquisition are steel, power, and mining.

**Figure 7. India Land Use – Mn Sq Km**

Use	Area
<b>Geographical Area</b>	<b>3.29</b>
Of which:	
Forests	0.69
Agri Land	1.43
Barren/Fallow Land	0.93
Others	0.23

Source: Ministry of Agriculture


## 3. Environmental Clearances

The current environmental clearance process is viewed to be complex and tedious. Industries and projects have to seek up to four clearances from the Centre pertaining to environment, wildlife, forestry and coastal zone regulations. Each of these clearances requires separate procedures. The need for clearance from 4 different divisions creates more room for delay and increases risk of a project being denied approval. Furthermore, disagreement in judgment between ministries and corruption allegations in cases of approval of controversial projects further hinders the clearance process.

# National Investment Board – Can it Help?

## PM/FM – Focus on getting growth back on track

Figure 8. Trends in Invest & GDP (%)



Source: CSO

Following the recent reforms in fuel prices, FDI and divestments, the Prime Minister has acknowledged the need to speed up implementation of infra projects to remove "supply bottlenecks which constrain growth in other sectors, and also for boosting investor sentiment to raise the overall rate of investment". The PM has decided to personally review the infrastructure sector performance in the first six months to ensure project timelines are met.

Echoing him, the Finance Minister has said "outcomes must be measured not only in terms of achieving the financial outlays but also achieving the physical targets" and has proposed the setting up of a National Investment Board.

## National Investment Board

The National Investment Board is expected to play a major role in reducing delays caused by interaction of 4 separate regulation systems, and would simplify the clearance process. The FM has proposed that the responsibility to make final decisions should be vested in one single authority - the National Investment Board. This NIB would be chaired by the PM and its authority should extend to proposals/projects where the investment is above a threshold of Rs10bn. The Allocation of Business Rules should be amended to create such a mechanism so that final decisions at a Cabinet level are made quicker. "Once the final decision is taken by the National Investment Board, no other Ministry or Department or Authority should be able to interfere with that decision or delay its implementation" said Chidambaram.

**Will it be welcome?** — The proposal for a National Investment Board is expected to be taken up by the Cabinet during its next meeting. The finance minister's proposal is welcome as it would impact many industry sectors on different points of the supply line, and positively impact growth. Development of facilities in sectors such as roads and highways and power would greatly add to much-needed connectivity and resources.

**What may not change** — It is unclear whether the NIB will be involved only in clearances or it will also monitor the progress of projects. If the former is true, it could help improve coordination and efficiency at the clearance stage, but project progress at other stages would remain unchanged. Moreover, the NIB would be at a central level, hence, state-level projects may still remain stalled.

## Politics – How Do The Numbers Stand Up?

The initial announcement of reforms was followed by a variety of reactions on the political front. While the Prime Minister stood in support of reforms, saying "We have to bite the bullet, if we have to go down, let us go down fighting", the decision was not received with as much favor from both the Opposition and key UPA allies.

**Still searching for solid ground** — After the fallout with the TMC, the government now needs support of the Samajwadi Party (SP) and Bahujan Samaj Party (BSP) for the passage of the newly approved insurance and pension bills. Both these parties have not shown clear support for recent FDI decisions, but have backed the government in Parliament. The SP has said "it is important for us to support the government against communal forces" and that it will "take an appropriate stand when the time comes".

**Opposition Matters** – As seen in figure 9, the UPA is now a 'minority govt'. While it needs the support of the 'external parties' to pass the insurance and pension bill, interestingly, these reforms were originally drafted by the BJP during the NDA regime. Meanwhile, the Left is against the reforms and has said it will "oppose these decisions inside and outside parliament".

**Politics: Never say never** — While the government appears to have the numbers in place, the key in politics is "Never Say Never". The TMC's withdrawal could undermine the Congress party's support within its allies. Moreover, the current largest ally, the DMK (18 seats) also opposes the reforms but has said that it "won't embarrass the govt and take an extreme step". The Samajwadi party (22 seats), which provides external support to the UPA, has also stated it is "not to be taken for granted" and it is expected to announce the status of its ties with the UPA on October 10.

Figure 9. Current Composition of Lok Sabha

Party	Seats	Party	Seats
Indian National Congress(INC)	205	Bharatiya Janata Party(BJP)	114
Dravida Munnetra Kazhagam(DMK)	18	Janata Dal (United) (JD(U))	20
Nationalist Congress Party(NCP)	9	Shiv Sena(SS)	11
J&K National Conference(JKNC)	3	Shiromani Akali Dal(SAD)	4
Indian Union Muslim League (IUML)	2	Telangana Rashtra Samithi(TRS)	2
Rashtriya Lok Dal(RLD)	5	Biju Janata Dal(BJD)	14
Others/ Independents	13	AIADMK	9
<b>UPA</b>	<b>255</b>	Telugu Desam Party(TDP)	6
<b>Supporting Parties</b>		Janata Dal (Secular) (JD(S))	3
Samajwadi Party(SP)	22	All India Trinamool Congress TMC	19
Bahujan Samaj Party(BSP)	21	Jharkhand Vikas Morcha JVM (P)	2
Rashtriya Janata Dal(RJD)	4	Left Demo. Front	25
<b>Total:</b>	<b>47</b>	Others	11
		<b>Total</b>	<b>240</b>
<b>UPA Incl. Outside Support:</b>	<b>302</b>	<b>TOTAL LOK SABHA</b>	<b>542</b>

Source: www.loksabha.nic.in


Figure 10. Current Composition of Rajya Sabha

Party	Seats	Party	Seats
Indian National Congress(INC)	70	Bharatiya Janata Party(BJP)	49
DMK	7	Janata Dal (United) (JD(U))	9
Nationalist Congress Party (NCP)	7	Shiv Sena(SS)	4
J&K National Conf (JKNC)	2	Shiromani Akali Dal(SAD)	3
Rashtriya Lok Dal(RLD)	5	India National Lok Dal (INLD)	1
<b>UPA</b>	<b>91</b>	Biju Janata Dal(BJD)	7
<b>Supporting Parties</b>		Asom Gana Parishad (AGP)	2
Samajwadi Party(SP)	9	Telugu Desam Party (TDP)	5
Bahujan Samaj Party(BSP)	15	AIADMK	5
Rashtriya Janata Dal(RJD)	2	Left Parties	12
Bodoland People's Front (BPF )	1	All India Trinamool Congress TMC	9
Lok Janasakti Party (LJP )	1	<b>Total NDA:</b>	<b>106</b>
Mizo National Front (MNF )	1		
Nagaland People's Front (NPF)	1	Nominated	10
<b>Total:</b>	<b>30</b>	Other Parties/ Independents	7
<b>UPA Incl. Outside Support:</b>	<b>121</b>	<b>TOTAL RAJYA SABHA</b>	<b>244</b>

Source: www.rajyasabha.nic.in

## Kelkar Committee – Will the Reco's Be Implemented?

Figure 11. Trends in Centre's Deficit (%)



Source: Citi Research

Pursuant to the Finance Minister, P Chidambaran's statement on Aug 6 regarding the need for fiscal correction, a 3 member panel headed by Dr. Vijay Kelkar and including Dr Indira Rajaraman and Dr Sanjiv Misra was set up to assist Govt. in formulating the path to fiscal consolidation. The report submitted by the Committee states the economy is currently "poised on edge of a fiscal precipice" with a likely fiscal deficit of ~6.1% GDP in 2012-13 unless immediate measures are taken.

The report concludes on the note: **"We cannot over-emphasize the need and the urgency of fiscal consolidation"** and puts forth recommendations to contain current year fiscal deficit at 5.2% of GDP vs. 5.1% of GDP for FY13BE.

### Implementation of Recommendations

The govt is expected to announce a 5 year fiscal consolidation plan that will lay down objectives to steadily narrow the fiscal gap. Moreover, the PM is focused on accelerating direct cash transfers to beneficiaries through Aadhaar linked bank accounts while the FM has decided to personally scrutinize all expenditures above INR 2bn.

However, the gradual phasing out of subsidies, as suggested by the Kelkar Committee report, has not found favour with the Government. The Dept. of Economic Affairs issued a statement saying some of the recommendations appear contrary to the declared objective of the Government of 'sustained and inclusive growth'. The FM has also been quoted as saying *"We can't wish away subsidies, but can improve their delivery."* The Union Food Ministry has also expressed reservation against pruning of the food subsidy bill and has said it will convey its opposition to Finance Ministry soon.

Figure 10. Key Recommendations of Kelkar Committee

Tax Measures to contain tax GDP ratio at 10.3	Divestment to attain INR 300bn as per FY13BE	Subsidies to contain it at 2.2% GDP as per FY13 BE	Plan Expenditure to increase saving by INR 200bn
Comprehensive review of the Direct Taxes Code Bill & more services brought under the tax net	Use of Offer For sale (OFS), Call Option Model, Exchange Traded Fund to get market prices for divestments and offer diversification to investor	<b>Petroleum subsidy</b> a. Price rise: diesel by Rs 4/ltr, kerosene by Rs 2/ltr & LPG by Rs 50 per cylinder b. Regular adjustment & eventual decontrol of diesel	Proper prioritization and efficient use of available resources through reallocation across schemes
Profiling of all taxpaying individuals and institutions to help decrease tax evasion and tax fraud	Disinvestment of minority government equity stakes in private entities, such as the holdings in SUUTI, HZL and BALCO	<b>Fertilizer Subsidy</b> a. Dept of Fertilizer's price increase mechanism to be introduced b. Regular hike in urea prices to close gap between urea and P&K fertilizer	Better designing and targeting to plug leakages from the Plan
Pending refunds to be issued at the earliest to improve liquidity of tax payers		<b>Food Subsidy</b> a. Progressive reduction in food subsidy b. Remove levy on sugar & controls from non levy sugar c. Initiate direct cash transfer for subsidies d. Appropriate phasing of Food Security Bill accounting for fiscal challenges	Monitoring, esp of downstream expenditure deployment by Planning Commission
Negative list of services should be reviewed for "further pruning"			
Mandatory PAN /UID in all electronic transactions to reduce use of black money			
Expedite implementation of the GST regime			

Source: Kelkar Committee Report

## Quick Re-cap of our Views

As mentioned in our note, [Govt Delivers beyond Expectations – Bodes Well for the Macro and All Asset Classes](#), dated Sept 17 2012, the macro implications of the reform measures are unanimously positive.

### Extract from our note:

- **Growth – Bottom in Sight; Impact more in FY14:** These measures are a big sentiment positive, and bode well for both consumer and business confidence which have been on a downtrend. Moreover, this sets a good platform for addressing “execution” related issues that have resulted in a collapse in investments. However, we are maintaining our 5.4% GDP estimate for FY13 as the impact on the numbers will probably be felt towards the latter part of FY13 or FY14.
- **Balance of Payments and FX, Positive Impact in FY13** — On the capital account, while the long awaited measures relating to FDI in retail will aid flows in FY14, the ability and willingness of the govt to act despite coalition pressures bodes well for FDI in other sectors. However, reforms coupled with global liquidity easing are a big positive for portfolio flows. Thus, despite the recent uptrend in oil prices, we maintain our view of the current account deficit improving from 4.2% of GDP in FY12 to 3% in FY13. All of this points to a further appreciation in the INR.
- **Inflation and Rates** — While the fuel price measures will result in headline inflation increasing by ~125bps, key to note is that the RBI has been stating that inflation rising due to measures taken to reduce ‘suppressed’ inflation will not be viewed negatively. Thus while the positive effects of retail on inflation via a reduction in easing supply side bottlenecks should be felt only in the medium term, we maintain our view that headline inflation is likely to average 8% in FY13.
- **Will the RBI follow?** — Despite inflation likely to remain well above the RBI’s medium target of 4%-5%, we maintain our view of the RBI easing by a further 50bps in FY13. Prior to these measures we had expected easing only in 2HFY13, however, post these measures, the probability of monetary action in its policy today/mid policy measures has risen considerably.
- **Fisc and Ratings: Slippage for sure, but rating concern comes off now** — As mentioned earlier, given the unrealistic subsidy estimates, despite the fuel price hike, we expect the deficit to touch 5.9% of GDP vs. budget estimates of 5.1%. More-over the divestments announced are expected to bring in Rs150bn while the budgeted numbers are at Rs300bn. None-the-less, the reform measures send a strong signal and are likely to reduce concerns of a ratings downgrade



## Appendix A-1

### Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

### IMPORTANT DISCLOSURES

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at [https://www.citivelocity.com/cvr/eppublic/citi\\_research\\_disclosures](https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures). Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

### NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets India Private Limited

Rohini Malkani

### OTHER DISCLOSURES

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

**Important Disclosures for Morgan Stanley Smith Barney LLC Customers:** Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Research research report. Ask your Financial Advisor or use [smithbarney.com](http://smithbarney.com) to view any available Morgan Stanley research reports in addition to Citi Research research reports.

Important disclosure regarding the relationship between the companies that are the subject of this Citi Research research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at [www.morganstanleysmithbarney.com/researchdisclosures](http://www.morganstanleysmithbarney.com/researchdisclosures).

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to [www.morganstanley.com/researchdisclosures](http://www.morganstanley.com/researchdisclosures) and [https://www.citivelocity.com/cvr/eppublic/citi\\_research\\_disclosures](https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures).

This Citi Research research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of Citi Research. This could create a conflict of interest.

**The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by.** The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comisión Nacional Bancaria y de Valores. Reforma 398, Col. Juárez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ("FAA") through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any

information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at [https://www.citivelocity.com/cvr/eppublic/citi\\_research\\_disclosures](https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures).

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual

preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

---

© 2012 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

---

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST

---